AZ and Novoheart collaborate on 'heart in a jar', to develop...

Stem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will be used to help develop new heart failure drugs.

Novartis eyes $5bn The Medicines Company acquisition - repor...

Novartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for a deal that could expand its pipeline of cardiac medicines, according to p

Amgen pulls higher-priced Repatha to try to lift sales

FDA approves AZ's Farxiga in new heart failure prevention us...

The FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in adults with type 2 diabetes and other cardiovascular risks.<

AI-driven atrial fibrillation project begins after seed fund...

Clinical development of an AI-driven system that identifies the sources or drivers of atrial fibrillation (AF), and could prevent the need for medication, has got off the ground after the p

Heart failure results could unlock key market for Farxiga - ...

AstraZeneca doesn’t quite know why its diabetes drug Farxiga is also working in patients with heart failure – but what it does know is that, if approved in this new use on this basis, it co